Showing results (121-130 of 144) with videos related to
Sort By:
Pageof 15
International Journal of Molecular Sciences|July 3, 2020
Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?Sylwia Szpak-Ulczok, Aleksandra Pfeifer, Dagmara Rusinek, et al.The Journal of Clinical Endocrinology and Metabolism|July 30, 2013
Genome-wide association study on differentiated thyroid cancerAleksandra Köhler, Bowang Chen, Federica Gemignani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Cabozantinib in progressive medullary thyroid cancerRossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2017
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid CancerXiaopei Shen, Guangwu Zhu, Rengyun Liu, et al.Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinomaKyeong J Kim, Sin G Kim, Jie Tan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2018
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerFei Wang, Shihua Zhao, Xiaopei Shen, et al.The New England Journal of Medicine|October 23, 2023
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid CancerJulien Hadoux, Rossella Elisei, Marcia S Brose, et al.Journal of the National Cancer Institute|November 23, 2017
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision TreatmentYueye Huang, Shen Qu, Guangwu Zhu, et al.The Journal of Clinical Endocrinology and Metabolism|July 17, 2021
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid CancerYubing Tao, Fei Wang, Xiaopei Shen, et al.Pageof 15